27 April 2022 | News
In 2021, Abcam achieved the top market share in antibody citations for research, with over 70,000 publications citing its products
Abcam, a global innovator working together with life scientists to advance research and enable faster breakthroughs, officially opens its newest regional hub in Singapore.
With healthcare expenditure in Asia projected to grow by 135% to $2.3 trillion come 2026, the life sciences sector in the region continues to expand rapidly.
Abcam’s new site will service the growing APAC life sciences community, offering scientific and technical support and providing a commercial headquarters for the region.
Alan Hirzel, CEO at Abcam said, "The new regional hub will strengthen our interactions with researchers in APAC and will help the global life sciences community push the boundaries of research.”
At its new base at the Biopolis Biomedical Research Hub, Abcam joins over 350 life sciences companies, including eight of the top 10 global pharma players, that have laid down roots in the country.
The official opening ceremony was graced by Guest-of-Honor Professor Tan Sze Wee, Assistant Chief Executive of Enterprise at Singapore’s Agency for Science, Technology and Research (A*STAR), alongside members of Abcam’s Executive Leadership team. This move marks a major milestone in Abcam’s growth, building on its recent expansion in Shanghai and Hangzhou (which continuesto serve customers in mainland China) and Adelaide, Australia.